about
The suppressive tumor microenvironment: a challenge in cancer immunotherapy.Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells.Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy of MHC class I-deficient tumors.
@en
Immunotherapy of MHC class I-deficient tumors.
@nl
type
label
Immunotherapy of MHC class I-deficient tumors.
@en
Immunotherapy of MHC class I-deficient tumors.
@nl
prefLabel
Immunotherapy of MHC class I-deficient tumors.
@en
Immunotherapy of MHC class I-deficient tumors.
@nl
P2860
P356
P1433
P1476
Immunotherapy of MHC class I-deficient tumors.
@en
P2093
Milan Reiniš
P2860
P304
P356
10.2217/FON.10.128
P407
P577
2010-10-01T00:00:00Z